Discover and read the best of Twitter Threads about #CVCT2021
Most recents (5)
Such an important topic!Sex-related eligibility criteria leading to exclusion of women from clinical trials. @hvanspall proposes pragmatic eligibility criteria facilitating enrolment of women &URM in RCTs
#CVCT2021 @CVCTForum @SantosGallegoMD @DrRaniKhatib @drdargaray
#CVCT2021 @CVCTForum @SantosGallegoMD @DrRaniKhatib @drdargaray
Brilliant slide by @hvanspall on strategies to increase diversity in clinical trials
#CVCT2021 @CVCTForum @docbhardwaj @SantosGallegoMD @AHajduczok @DrRaniKhatib @Drroxmehran @DrRajivsankar @rachkataria @FaiezZANNAD @drdargaray @ShahzebKhanMD @DVervoort94 @SolovevaAnzhela
#CVCT2021 @CVCTForum @docbhardwaj @SantosGallegoMD @AHajduczok @DrRaniKhatib @Drroxmehran @DrRajivsankar @rachkataria @FaiezZANNAD @drdargaray @ShahzebKhanMD @DVervoort94 @SolovevaAnzhela
@FaiezZANNAD on geographic equity in CV clinical trials:increasing research capacity & trial enrolment in LMIC Case in point:MENA region
#CVCT2021 @CVCTForum @docbhardwaj @DjawidHashemi @DrRaniKhatib @hvanspall @DrRajivsankar @drdargaray @DVervoort94 @mirvatalasnag @Hragy
#CVCT2021 @CVCTForum @docbhardwaj @DjawidHashemi @DrRaniKhatib @hvanspall @DrRajivsankar @drdargaray @DVervoort94 @mirvatalasnag @Hragy
Dominick Angiolillo on the dilemma of perioperative antiplatelet therapy
#CVCT2021 @CVCTForum @docbhardwaj @SantosGallegoMD @AHajduczok @DrRaniKhatib @hvanspall @DrRajivsankar @rachkataria @FaiezZANNAD @drdargaray @ShahzebKhanMD @DVervoort94 @SolovevaAnzhela @cristina_gavina
#CVCT2021 @CVCTForum @docbhardwaj @SantosGallegoMD @AHajduczok @DrRaniKhatib @hvanspall @DrRajivsankar @rachkataria @FaiezZANNAD @drdargaray @ShahzebKhanMD @DVervoort94 @SolovevaAnzhela @cristina_gavina
Some great insights on limitations of perioperative antiplatelet Rx & limitations of guidelines - the issue perioperative antiplatelet and HBR are not the same! #CVCT2021 @CVCTForum @docbhardwaj @SantosGallegoMD @AHajduczok @DrRaniKhatib @DrRajivsankar @FaiezZANNAD @DLBHATTMD
Basic concepts on bridging antiplatelets and why #cangrelor is best suited
#CVCT2021 @CVCTForum @docbhardwaj @SantosGallegoMD @AHajduczok @DrRaniKhatib @hvanspall @DrRajivsankar @mirvatalasnag @SuzanneJBaron @DLBHATTMD @Pooh_Velagapudi @sabeedak1 @SABOURETCardio
#CVCT2021 @CVCTForum @docbhardwaj @SantosGallegoMD @AHajduczok @DrRaniKhatib @hvanspall @DrRajivsankar @mirvatalasnag @SuzanneJBaron @DLBHATTMD @Pooh_Velagapudi @sabeedak1 @SABOURETCardio
The regulatory viewpoint of endpoints in antithrombotic therapy trials by Ellis Unger #CVCT #iCVCT @docbhardwaj @DrRajivsankar @DrRaniKhatib @SantosGallegoMD @CMichaelGibson @hvanspall @CVCTForum @rachkataria @lucreciamburgos @AHajduczok @Drroxmehran @djc795 @A_FelixOliveira
The regulatory viewpoint of endpoints in antithrombotic therapy trials by Ellis Unger #CVCT2021 @docbhardwaj @DrRajivsankar @DrRaniKhatib @SantosGallegoMD @CMichaelGibson @hvanspall @CVCTForum @rachkataria @lucreciamburgos @AHajduczok @DjawidHashemi @BoldiKovacsMD @ZainabDakhil2
How different should anti XIa trials be: @CMichaelGibson weighs in on population, endpoints, duration of therapy, disease states?
#CVCT2021 @docbhardwaj @DrRajivsankar @DrRaniKhatib @SantosGallegoMD @CMichaelGibson @hvanspall @CVCTForum @rachkataria @lucreciamburgos @AHajduczok
#CVCT2021 @docbhardwaj @DrRajivsankar @DrRaniKhatib @SantosGallegoMD @CMichaelGibson @hvanspall @CVCTForum @rachkataria @lucreciamburgos @AHajduczok
#ICPeeps next up: the first session of #iCVCT #CVCT2021 on hemodynamic support trials with ⭐ panel
@alaide_chief @NavinKapur4 @thiele_holger @georgedangas et al.
@CVCTForum @Drroxmehran @CMichaelGibson @mirvatalasnag @ShrillaB @Babar_Basir @adityadoc1 @DrRaniKhatib @ShrillaB
@alaide_chief @NavinKapur4 @thiele_holger @georgedangas et al.
@CVCTForum @Drroxmehran @CMichaelGibson @mirvatalasnag @ShrillaB @Babar_Basir @adityadoc1 @DrRaniKhatib @ShrillaB
Despite ESC recommendations IABP remains most widely used MCS in Germany: European perspectives and trends in MCS by @alaide_chief
#CVCT #iCVCT @NavinKapur4 @thiele_holger @georgedangas @CVCTForum @Drroxmehran @ShrillaB @Babar_Basir @adityadoc1 @DrRaniKhatib @docbhardwaj
#CVCT #iCVCT @NavinKapur4 @thiele_holger @georgedangas @CVCTForum @Drroxmehran @ShrillaB @Babar_Basir @adityadoc1 @DrRaniKhatib @docbhardwaj
Heterogenic use of #MCS in Europe dictated by country specific policies, cost and availability
@alaide_chief
#CVCT #iCVCT @NavinKapur4 @thiele_holger @georgedangas @CVCTForum @Drroxmehran @hvanspall @rachkataria @AHajduczok @DrRajivsankar @DrRaniKhatib @SantosGallegoMD
@alaide_chief
#CVCT #iCVCT @NavinKapur4 @thiele_holger @georgedangas @CVCTForum @Drroxmehran @hvanspall @rachkataria @AHajduczok @DrRajivsankar @DrRaniKhatib @SantosGallegoMD
fantastic takeaway slides on subgroup analyses & secondary results publications by @FaiezZANNAD
#CVCT2021 @hvanspall @DjawidHashemi @rachkataria @SantosGallegoMD @AlexNowbar @DrRajivsankar @cristina_gavina @A_FelixOliveira @BoldiKovacsMD @docbhardwaj @drdargaray
#CVCT2021 @hvanspall @DjawidHashemi @rachkataria @SantosGallegoMD @AlexNowbar @DrRajivsankar @cristina_gavina @A_FelixOliveira @BoldiKovacsMD @docbhardwaj @drdargaray
Dr Joseph Hill @CircAHA on the nuances and challenges with publishing artificial intelligence analyses of trial databases:
#CVCT2021 @hvanspall @rachkataria @SantosGallegoMD @AlexNowbar @DrRajivsankar @cristina_gavina @A_FelixOliveira @BoldiKovacsMD @docbhardwaj @drdargaray
#CVCT2021 @hvanspall @rachkataria @SantosGallegoMD @AlexNowbar @DrRajivsankar @cristina_gavina @A_FelixOliveira @BoldiKovacsMD @docbhardwaj @drdargaray
@cardiobrief Larry Husten raises an important issue; should trials be released to the press before full publication is available?
#CVCT2021 @hvanspall @rachkataria @SantosGallegoMD @AlexNowbar @CVCTForum @drdargaray @DrRajivsankar @DrRaniKhatib @AHajduczok
#CVCT2021 @hvanspall @rachkataria @SantosGallegoMD @AlexNowbar @CVCTForum @drdargaray @DrRajivsankar @DrRaniKhatib @AHajduczok
